尼罗替尼治疗慢性髓样白血病的不良反应及处理  

Management of adverse events on nilotinib therapy for treatment of CML

作　　者：韩丹壘[1] 郭静明[1] 

机构地区：[1]三峡大学第一临床医学院血液内科,湖北宜昌443000

出　　处：《中国新药与临床杂志》2013年第4期327-330,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：尼罗替尼,主要用于新诊断为慢性髓样白血病(CML)的患者和大多数对于伊马替尼抵抗的CML患者。尼罗替尼作用优于伊马替尼,其最优剂量,长期使用的安全性以及患者的选择仍然是一个比较关注的问题。众多临床试验数据显示,使用尼洛替尼治疗CML,主要的不良反应有骨髓抑制、皮疹、胃肠道反应以及心脏毒性等,本文就尼罗替尼治疗CML的不良反应及其处理作一综述。Nilotinib exerts major anti-leukemic effects in newly diagnosed patients with chronic myeloid leukemia （CML） as well as in most patients with imatinib-resistant CML. The anti-leukemic activity of nilotinib exceeds that of imatinib. However, several questions concerning the optimal dose, follow-up parameters, long- term safety, and patient selection remain open. Many clinical trial data suggested that the major adverse reactions of nilotinib in the treatment of CML are myelosuppression, skin rashes, gastrointestinal abnormalities,cardiotoxicity and so on. The clinical management of the adverse reactions are reviewed in this paper.

关 键 词：尼罗替尼 白血病 髓样 慢性期 药物不良反应 药物疗法 

分 类 号：R979.1[医药卫生—药品]